KPTI — Karyopharm Therapeutics Share News
0.000.00%
Last trade - 00:00- $11.74m
- $268.91m
- $146.07m
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview
Karyopharm Therapeutics Inc. expected to post a loss of $1.28 a share - Earnings Preview
Karyopharm hits record low after endometrial cancer trial miss
U.S. RESEARCH ROUNDUP-Apple, Amazon, Mastercard
NASDAQ RESUMED AT 04:40 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:01 PM
Brief: Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Karyopharm Q1 net loss narrows
Brief: Karyopharm Therapeutics: Selling Stockholder May Resell Up To 8,843,036 Shares Of Karyopharm Common Stock - SEC Filing
Brief: Karyopharm Therapeutics May Offer Up To $400 Million In Securities - SEC Filing
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
Street View: Karyopharm's cancer drug trial results limit regulatory odds
U.S. STOCKS ON THE MOVE-Dollar General, software stocks, Sable Offshore
U.S. STOCKS ON THE MOVE-FedEx, Estee Lauder, Janus Henderson